Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.64 |
| ▸ | MAOA | P21397 | 9/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332876 | 0.87 | HTT (0.59) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL30199790 | 0.87 | HTT (0.59) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL18307137 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL3599640 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL4219649 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL6015836 | 0.78 | MAOB (1.00) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL279937 | 0.78 | EPHX2 (1.00) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL31469916 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL5751107 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL3599644 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3790551-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-10093683-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3134408-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | disclosed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | disclosed |
| US-6794373-B2 | ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT | WYETH | 2004-09-21 | — | — | US | disclosed |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | LIGAND PHARMACEUTICALS INCORPORATED | 2002-10-17 | — | — | US | disclosed |
| US-20020115853-A1 | Benzimidazolones and analogues | WYETH | 2002-08-22 | — | — | US | disclosed |
| US-6423699-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-1173213-A1 | COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1173423-A1 | BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066564-A1 | BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066168-A1 | COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | PDF, FDPS, DCTPP1 | MAOB 1875/4885MAOA 2171/4885EPHX2 3591/4885 |
| US-20170044183-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | MAOB 830/4885MAOA 799/4885EPHX2 233/4885 |
| US-10093683-B2 | Factor XIa inhibitors | F11, F12, SERPINC1 | MAOB 917/4885MAOA 799/4885EPHX2 270/4885 |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | PGR, GNRHR, NR4A1 | MAOB 1637/4885MAOA 1529/4885EPHX2 3634/4885 |
| US-20020115853-A1 | Benzimidazolones and analogues | PGR, NR5A1, NR3C2 | MAOB 2264/4885MAOA 2387/4885EPHX2 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.